(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use
|
|
- Ezra Roland Wells
- 5 years ago
- Views:
Transcription
1 ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1
2 Austria Austria Bulgaria Bulgaria Czech Republic Czech Republic Roche Austria GmbH, Kytril 3 mg - Engelhorngasse 3, 1211 Wien Injektionslösung Austria Roche Austria GmbH, Engelhorngasse 3, 1211 Wien Austria Roche Bulgaria EOOD, 16 Bialo Pole Str Sofia Bulgaria Roche Bulgaria EOOD, 16 Bialo Pole Str Sofia Bulgaria Roche s.r.o., Dukelských hrdinů Praha 7 Czech Republic Roche s.r.o., Dukelských hrdinů Praha 7 Czech Republic 3 mg/3 ml Solution for Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use Kytril solution injectable Kytril 3 mg/3 ml solution injectable Kytril 1 mg comprimés pelliculés 1 mg Solution for 3 mg Solution for Kytril 1 mg / ml Solution for /infusion Kytril 2 mg 2 mg Film-coated tablet Oral use Kytril inj./inf Solution for /infusion 3 ml 3 mg/3 ml 1 ml (1 mg/ ml) 3 ml (1 mg/ ml) 2
3 Estonia Estonia Roche Eesti OÜ Lõõtsa 2, Tallinn Estonia Roche Eesti OÜ Lõõtsa 2, Tallinn Estonia Roche Oy PL Espoo Roche Oy PL Espoo Roche Oy PL Espoo ROCHE 52 Boulevard du Parc NEUILLY SUR SEINE cedex ROCHE 52 Boulevard du Parc NEUILLY SUR SEINE cedex ROCHE 52 Boulevard du Parc NEUILLY SUR SEINE cedex Kytril 1mg/ml Concentrate for /infusion Kytril 1mg Film-coated tablet Oral use Kytril Kytril Solution for Kytril 3mg/3ml solution injectable pour voie intraveineuse Kytril 1mg/ comprimé pelliculé Kytril 2 mg comprimé pelliculé 3mg/3ml Solution for 2 mg Film-coated tablet Oral use 1mg/ml (1ml and 3ml) 5x1 ml and 5x3 ml 3mg/3ml 3
4 Roche Pharma AG Emil-Barell-Straße Grenzach-Wyhlen Roche Pharma AG Emil-Barell-Straße Grenzach-Wyhlen Roche Pharma AG Emil-Barell-Straße Grenzach-Wyhlen Greece Roche (Hellas ) A.E. Alamanas 4 & Delfon, Maroussi Greece Greece Roche (Hellas ) A.E. Alamanas 4 & Delfon, Maroussi Greece Greece Roche (Hellas ) A.E. Alamanas 4 & Delfon, Maroussi Greece Greece Roche (Hellas ) A.E. Alamanas 4 & Delfon, Maroussi Greece Hungary Roche (Hungary) Ltd H-2040 Budaörs Edison u. 1. Hungary Kevatril 1 mg Solution for Injektionslösung Kevatril Filmtabletten 2 mg 2 mg Film-coated tablet Oral use Kevatril 3 mg Solution for 3 mg/3 ml Injektionslösung Kytril 1mg Film-coated tablet Oral use Kytril 1mg/1ml Solution for Kytril 3mg/3ml Solution for Kytril 1 ml 3 ml 1mg/1ml 3mg/3ml 4
5 Hungary Ireland Ireland Ireland Ireland Roche (Hungary) Ltd H-2040 Budaörs Edison u. 1. Hungary Roche S.p.A. Piazza Durante Milano Roche S.p.A. Piazza Durante Milano Roche S.p.A. Piazza Durante Milano Kytril 3 mg/3 ml Solution for Kytril Tablets 1mg 1mg Film-coated tablet Oral use Kytril Tablets 2mg 2mg Film-coated tablet Oral use Kytril Ampoules concentrate for infusion or Kytril Infusion 3 mg/3 ml concentrate for infusion or 1mg/1ml 3mg/3ml Concentrate for infusion/ Concentrate for infusion/ Kytril 3 mg/3 ml Solution for Kytril Solution for Kytril 3 mg/5 ml Solution for 3 mg/3 ml 1ml contains 1mg granisetron (hydrochloride) 1mg contains 9mg sodium chloride = 3.54 mg sodium 3ml contains 3mg granisetron (hydrochloride) 3ml contains 27mg sodium chloride = mg sodium 3 mg/3 ml 3 mg/5 ml 5
6 Latvia Latvia Luxembourg Luxembourg Roche S.p.A. Piazza Durante Milano Roche S.p.A. Piazza Durante Milano Roche Latvija SIA G. Astras 8b Riga, LV-1082 Latvia Roche Latvija SIA G. Astras 8b Riga, LV-1082 Latvia UAB Roche Lietuva J. Jasinskio 16b, LT Vilnius UAB Roche Lietuva J. Jasinskio 16b, LT Vilnius UAB Roche Lietuva J. Jasinskio 16b, LT Vilnius Kytril Kytril Kytril 1 mg film-coated tablets Solution for Kytril 1mg Film-coated tablet Oral use Kytril 1mg/ml Solution for /infusion Kytril 3mg/3ml Solution for /infusion Kytril solution injectable Kytril 3 mg/3 ml solution injectable 1 mg Solution for 3 mg Solution for 3 mg/3 ml 3 mg/3 ml 6
7 Luxembourg Malta Malta Kytril 1 mg comprimés pelliculés Roche Nederland B.V., Kytril i.v. 3 mg = 3 ml, Postbus 44, 3440 AA Woerden oplossing voor injectie Roche Nederland B.V., Kytril i.v. 1 mg = 1 ml, Postbus 44, 3440 AA Woerden oplossing voor injectie Roche Nederland B.V., Kytril 1 mg tabletten, Postbus 44, 3440 AA Woerden omhulde tabletten Roche Nederland B.V., Kytril 2 mg tabletten, Postbus 44, 3440 AA Woerden omhulde tabletten Roche Farmacêutica Química, Lda Estrada nacional 249-1, , Amadora Roche Farmacêutica Química, Lda Estrada nacional 249-1, , Amadora Kytril Tablets 1mg 1mg Film-coated tablet Oral use Kytril Injection 3mg/3ml 3mg/3ml Concentrate for infusion/ Solution for Solution for 2 mg Film-coated tablet Oral use Kytril 1ml contains 1mg granisetron (hydrochloride) 7
8 Romania Romania Slovak Republic Slovak Republic Slovak Republic Roche Farmacêutica Química, Lda Estrada nacional 249-1, , Amadora Roche Farmacêutica Química, Lda Estrada nacional 249-1, , Amadora Roche Romania SRL 9-9A Dimitrie Pompei Street, Building 19, Entrance B, 3rd Floor, Sector (District) 2, Bucharest Romania Roche Romania SRL 9-9A Dimitrie Pompei Street, Building 19, Entrance B, 3rd Floor, Sector (District) 2, Bucharest Romania Roche Slovensko s.r.o. Cintorínska 3/A Bratislava Slovak Republic Roche Slovensko s.r.o. Cintorínska 3/A Bratislava Slovak Republic F.Hoffmann-La Roche Ltd. Basel, Switzerland Roche farmacevtska družba d.o.o. Vodovodna cesta Ljubljana Kytril Solution for Kytril 3 mg/3 ml Solution for Kytril 1 mg Kytril 3mg/3ml Solution for Kytril 1 mg Kytril 2 mg 2 mg Film-coated tablet Oral use Kytril INJ/INF Concentrate for infusion/ Kytril 2 mg filmsko 2 mg Film-coated tablet Oral use obložene tablete 1 ml () 3 ml (3 mg/3 ml) 3mg/3ml (1mg/ml) 8
9 Roche farmacevtska družba d.o.o. Vodovodna cesta Ljubljana Roche farmacevtska družba d.o.o. Vodovodna cesta Ljubljana Roche Farma S.A. C/ Eucalipto Madrid Roche Farma S.A. C/ Eucalipto Madrid Roche Farma S.A. C/ Eucalipto Madrid Roche AB Box Stockholm Roche AB Box Stockholm Roche AB Box Stockholm Kytril raztopina za injiciranje Kytril 3 mg/3 ml raztopina za injiciranje Kytril 1 mg comprimidos recubiertos con película Kytril solución inyectable Kytril 3 mg/3 ml solución inyectable Solution for 3 mg/3 ml Solution for 1mg/1ml 3mg/3ml Solution for Solution for Kytril Kytril Solution for 5 x 1 ml 5 x 3 ml 9
10 AL7 1TW AL7 1TW AL7 1TW AL7 1TW Kytril Tablets 1mg 1mg Film-coated tablet Oral use Kytril Tablets 2mg 2mg Film-coated tablet Oral use Kytril Ampoule 1mg/1ml 1mg/1ml Concentrate for infusion/ Kytril Infusion 3mg/ml 3mg/3ml Concentrate for infusion/ 1ml contains 1mg granisetron (hydrochloride 1mg of granisetron per 1 ml solution 10
List of nationally authorised medicinal products
1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More information(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of and marketing authorisation holders in the Member s 1 Austria Austria Austria Austria Belgium Belgium Belgium
More informationANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
ANNEX I ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 4 A. MANUFACTURING AUTHORISATION HOLDERS Manufacturers
More informationAnnex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
More informationList of nationally authorised medicinal products
17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationMember State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing autorisation Holder
More information4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection
ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Route of ) Austria Bulgaria Cyprus Cyprus Czech Republic
More informationMember State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State Marketing Authorisation
More informationPowder for solution for infusion. Powder and solvent for solution for IM injection. Powder and solvent for solution for IV injection
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States 1 Member State EU/EEA Marketing authorisation
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Tamiflu 12 mg/ml powder for oral suspension oseltamivir
PACKAGE LEAFLET: INFORMATION FOR THE USER Tamiflu 12 mg/ml powder for oral suspension oseltamivir Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Tamiflu 12 mg/ml powder for oral suspension. oseltamivir
PACKAGE LEAFLET: INFORMATION FOR THE USER Tamiflu 12 mg/ml powder for oral suspension oseltamivir Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat
PACKAGE LEAFLET: INFORMATION FOR THE USER Xenical 120mg hard capsules Orlistat Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
More informationList of nationally authorised medicinal products
06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Tarceva 25 mg film-coated tablets Tarceva 100 mg film-coated tablets Tarceva 150 mg film-coated tablets Erlotinib Read all of this leaflet carefully before you
More informationAnnex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
More informationList of nationally authorised medicinal products
12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605
More informationPackage Leaflet: Information for the user. Perjeta 420 mg concentrate for solution for infusion pertuzumab
Package Leaflet: Information for the user Perjeta 420 mg concentrate for solution for infusion pertuzumab Read all of this leaflet carefully before you start being given this medicine because it contains
More information(Invented) Name Strength Pharmaceutical form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Austria Austria Austria
More informationMarketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal
More informationPackage leaflet: Information for the user Esbriet 267 mg hard capsules Pirfenidone
Appendix 1 Package leaflet: Information for the user Esbriet 267 mg hard capsules Pirfenidone This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat
PACKAGE LEAFLET: INFORMATION FOR THE USER Xenical 120mg hard capsules Orlistat Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again.
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More information1. What MabThera is and what it is used for
Package leaflet: Information for the patient MabThera 1400 mg solution for subcutaneous injection rituximab Read all of this leaflet carefully before you are given this medicine because it contains important
More informationPackage leaflet: Information for the patient. Cotellic 20 mg film-coated tablets cobimetinib
Package leaflet: Information for the patient Cotellic 20 mg film-coated tablets cobimetinib This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationSortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State EU/EEA Austria Austria
More informationBONVIVA 150 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER BONVIVA 150 mg film-coated tablets IBANDRONIC ACID This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationList of nationally authorised medicinal products
12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationMarketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Austria Austria Austria
More informationTadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation s in the member states 1 Austria Forest Pharma B.V. Newtonlaan
More informationList of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
More informationPackage leaflet: Information for the patient. Tecentriq 1,200 mg concentrate for solution for infusion atezolizumab
Package leaflet: Information for the patient Tecentriq 1,200 mg concentrate for solution for infusion atezolizumab This medicine is subject to additional monitoring. This will allow quick identification
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat
PACKAGE LEAFLET: INFORMATION FOR THE USER Xenical 120mg hard capsules Orlistat Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat
PACKAGE LEAFLET: INFORMATION FOR THE USER Xenical 120mg hard capsules Orlistat Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationPackage leaflet: Information for the patient. Ocrevus 300 mg concentrate for solution for infusion Ocrelizumab
Package leaflet: Information for the patient Ocrevus 300 mg concentrate for solution for infusion Ocrelizumab This medicine is subject to additional monitoring. This will allow quick identification of
More information(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Herceptin 600 mg solution for injection in vial Trastuzumab
PACKAGE LEAFLET: INFORMATION FOR THE USER Herceptin 600 mg solution for injection in vial Trastuzumab Read all of this leaflet carefully before you start using this medicine because it contains important
More informationPackage Leaflet: Information for the user. Tamiflu 6 mg/ml powder for oral suspension oseltamivir
Package Leaflet: Information for the user Tamiflu 6 mg/ml powder for oral suspension oseltamivir Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Hemlibra 150 mg/ml solution for injection. emicizumab
Package leaflet: Information for the user Hemlibra 150 mg/ml solution for injection emicizumab This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationPackage Leaflet: Information for the user. Tamiflu 6 mg/ml powder for oral suspension oseltamivir
Package Leaflet: Information for the user Tamiflu 6 mg/ml powder for oral suspension oseltamivir Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationB. PACKAGE LEAFLET 25
B. PACKAGE LEAFLET 25 PACKAGE LEAFLET: INFORMATION FOR THE USER PROTELOS 2 g granules for oral suspension Strontium ranelate Read all of this leaflet carefully before you start taking this medicine. -
More informationPackage leaflet: Information for the user. Zelboraf 240 mg film-coated tablets vemurafenib
Package leaflet: Information for the user Zelboraf 240 mg film-coated tablets vemurafenib Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationInvented name Strength. 125mg/5ml. 250mg/5ml
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States Member State (EU/EEA) Marketing Authorisation
More informationPackage leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride
Package leaflet: Information for the patient Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationPackage leaflet: Information for the user. Xeloda 150 mg film-coated tablets Xeloda 500 mg film-coated tablets capecitabine
Package leaflet: Information for the user Xeloda 150 mg film-coated tablets Xeloda 500 mg film-coated tablets capecitabine Read all of this leaflet carefully before you start taking this medicine because
More informationMarketing Authorisation Holder Invented name Strength Pharmaceutical Form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing Authorisation
More information(Invented) Name Strength Pharmaceutical form. Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml. 2.5 mg prolonged-release capsule, hard
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Boehringer Ingelheim RCV GmbH & Co KG, Dr.
More informationPackage leaflet: Information for the patient. MabThera 100 mg concentrate for solution for infusion rituximab
Package leaflet: Information for the patient MabThera 100 mg concentrate for solution for infusion rituximab Read this leaflet carefully before you start taking this medicine because it contains important
More informationPackage leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa
Package leaflet: Information for the user Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa Read all of this leaflet carefully before you start using this medicine because
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationPackage leaflet: Information for the patient. Xydalba 500 mg powder for concentrate for solution for infusion dalbavancin
Package leaflet: Information for the patient Xydalba 500 mg powder for concentrate for solution for infusion dalbavancin This medicine is subject to additional monitoring. This will allow quick identification
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Herceptin 150 mg powder for concentrate for solution for infusion Trastuzumab
PACKAGE LEAFLET: INFORMATION FOR THE USER Herceptin 150 mg powder for concentrate for solution for infusion Trastuzumab Read all of this leaflet carefully before you start using this medicine because it
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus L4 suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml
More informationPackage leaflet: Information for the patient. Fuzeon 90 mg/ml powder and solvent for solution for injection Enfuvirtide
Package leaflet: Information for the patient Fuzeon 90 mg/ml powder and solvent for solution for injection Enfuvirtide Read all of this leaflet carefully before you start using this medicine because it
More informationANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES 1 Member State EU/EEA Marketing Authorisation Holder Austria
More informationPackage leaflet: Information for the user. Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate
Package leaflet: Information for the user Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it
More informationPackage leaflet: Information for the user. Renvela 800 mg film-coated tablets sevelamer carbonate
Package leaflet: Information for the user Renvela 800 mg film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user CellCept 1 g/5 ml powder for oral suspension (mycophenolate mofetil)
Package leaflet: Information for the user CellCept 1 g/5 ml powder for oral suspension (mycophenolate mofetil) Read all of this leaflet carefully before you start taking this medicine because it contains
More informationList of nationally authorised medicinal products
29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPackage leaflet: Information for the patient. Gazyvaro 1,000 mg concentrate for solution for infusion Obinutuzumab
Package leaflet: Information for the patient Gazyvaro 1,000 mg concentrate for solution for Obinutuzumab This medicine is subject to additional monitoring. This will allow quick identification of new safety
More informationPackage leaflet: Information for the patient. Zeffix 100 mg film-coated tablets lamivudine
Package leaflet: Information for the patient Zeffix 100 mg film-coated tablets lamivudine Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to
More information1. What RoActemra is and what it is used for
Package leaflet: Information for the user RoActemra 162 mg solution for injection in pre-filled pen (ACTPen ) Tocilizumab Read all of this leaflet carefully before you start using this medicine because
More informationList of nationally authorised medicinal products
12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPackage leaflet: Information for the patient. Integrilin 2 mg/ml solution for injection eptifibatide
Package leaflet: Information for the patient Integrilin 2 mg/ml solution for injection eptifibatide Read all of this leaflet carefully before you start using this medicine because it contains important
More informationPackage leaflet: Information for the patient. Tadalafil Mylan 2.5 mg film-coated tablets Tadalafil
Package leaflet: Information for the patient Tadalafil Mylan 2.5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPackage leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride
Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using
More informationINN Product name Strength Pharmaceutical form
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation (s) in the member states 1 Targin 10 mg/5 mg prolongedrelease Targin 20 mg/10
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Metfmin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metfmin hydrochlide Read all of this leaflet carefully befe you start taking this medicine.
More informationOrlistat EG 60 mg capsule, hard oral use. Orlistat EG 120 mg capsule, hard oral use. Orlistat Sandoz 60 mg capsule, hard oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATIONS AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Belgium Belgium Belgium Belgium
More informationProduct name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln. Awegal inject 164,5 mg / 3 ml
Annex I List of the names, pharmaceutical s, strengths of the medicinal products, route of, marketing authorisation s in the Member States 1 Bulgaria Estonia Zentiva k.s. 130 U kabelovn Prague 10237 Czech
More information1. What RoActemra is and what it is used for
Package leaflet: Information for the user RoActemra 162 mg solution for injection in pre-filled syringe Tocilizumab Read all of this leaflet carefully before you start using this medicine because it contains
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equip WNV emulsion for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationPackage leaflet: Information for the user. Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal)
Package leaflet: Information for the user Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal) This medicine is subject to additional monitoring. This will allow quick identification
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user MIRCERA 30 micrograms/0.3 ml solution for injection in pre-filled syringe 40 micrograms/0.3 ml solution for injection in pre-filled syringe 50 micrograms/0.3 ml
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. AZILECT 1 mg tablets Rasagiline
PACKAGE LEAFLET: INFORMATION FOR THE USER AZILECT 1 mg tablets Rasagiline Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. -
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Vipidia 25 mg film-coated tablets Vipidia 12.5 mg film-coated tablets Vipidia 6.25 mg film-coated tablets alogliptin Read all of this leaflet carefully before
More informationPACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. chloroprocaine hydrochloride
Page 1 PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER Ampres 10 mg/ml solution for injection chloroprocaine hydrochloride Read all of this leaflet carefully before you are given this medicine
More informationB. PACKAGE LEAFLET 21
B. PACKAGE LEAFLET 21 PACKAGE LEAFLET: INFORMATION FOR THE USER Defitelio 80 mg/ml concentrate for solution for infusion Defibrotide This medicine is subject to additional monitoring. This will allow quick
More informationleflunomide Package leaflet: Information for the user Leflunomide Winthrop 20 mg film-coated tablets
Package leaflet: Information for the user Leflunomide Winthrop 20 mg film-coated tablets leflunomide Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationMarketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Savene 20 mg/ml powder for concentrate and diluent for solution for infusion.
PACKAGE LEAFLET: INFORMATION FOR THE USER Savene 20 mg/ml powder for concentrate and diluent for solution for infusion (dexrazoxane) Read all of this leaflet carefully before you start using this medicine
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. CIALIS 10 mg film-coated tablets tadalafil
PACKAGE LEAFLET: INFORMATION FOR THE USER CIALIS 10 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read
More informationCosaar 12,5 mg - Filmtabletten. Cosaar 50 mg - Filmtabletten. Cosaar 100 mg - Filmtabletten COZAAR CARDIO START. 21 X 12,5 mg + 14 X 50 mg
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S), ROUTE(S) OF ADMINISTRATION OF THE MEDICINAL PRODUCT(S), MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES Member State Marketing Authorisation
More informationPackage leaflet: Information for the user. Hemlibra 30 mg/ml solution for injection. emicizumab
Package leaflet: Information for the user Hemlibra 30 mg/ml solution for injection emicizumab This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationPACKAGE LEAFLET For medicinal products available on prescription
PACKAGE LEAFLET PACKAGE LEAFLET For medicinal products available on prescription Package leaflet: Information for the user Zirtek 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet
More informationPackage leaflet: Information for the user. Clopidogrel Mylan 75 mg film-coated tablets clopidogrel
Package leaflet: Information for the user Clopidogrel Mylan 75 mg film-coated tablets clopidogrel Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin
PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need
More informationList of nationally authorised medicinal products
12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationAnnex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection
07 March 2013 EMA/147828/2013 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation holders in the member states
More informationRead all of this leaflet carefully before you start using this medicine because it contains important information for you.
Package leaflet: Information for the patient Byetta 5 micrograms solution for injection in pre-filled pen Byetta 10 micrograms solution for injection in pre-filled pen exenatide Read all of this leaflet
More informationPackage leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin
Package leaflet: Information for the user Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this
More informationPackage leaflet: Information for the user. Benlysta 120 mg powder for concentrate for solution for infusion
Package leaflet: Information for the user Benlysta 120 mg powder for concentrate for solution for infusion Benlysta 400 mg powder for concentrate for solution for infusion Belimumab This medicine is subject
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Oprymea 0.088 mg tablets Oprymea 0.18 mg tablets Oprymea 0.35 mg tablets Oprymea 0.7 mg tablets Oprymea 1.1 mg tablets Pramipexole Read all of this leaflet
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More information